Table 3. Adjusted Relative Risk (aRR) with 95% confidence intervals (CI95%) of confirmed or hsCOVID-19 according to the presence of several comorbidities and treatments.

	N (All = 2102)	Model 1 - aRR (CI95%)	Model 2 - aRR (CI95%)
Women	1693	1.12 (0.71, 1.76)	1.11 (0.7, 1.76)
Age		0.99 (0.98, 1.01)	0.99 (0.98, 1.01)
Comorbidities
CV disease	314	1.84 (1.17, 2.87)	1.86 (1.19, 2.91)
Diabetes	264	1.2 (0.71, 2.03)	1.19 (0.7, 2.03)
Pulmonary disease	315	1.36 (0.76, 2.45)	1.34 (0.73, 2.46)
Chronic kidney disease	114	1.58 (0.82, 3.07)	1.56 (0.8, 3.03)
Cancer or active treatment	121	1.06 (0.46, 2.46)	1.06 (0.45, 2.47)
Treatments followed
Denosumab	264	0.58 (0.28, 1.22)	0.59 (0.28, 1.23)
Intravenous Zoledronate	179	0.62 (0.27, 1.41)	0.61 (0.27, 1.38)
Oral bisphosphonates	143	0.97 (0.45, 2.08)	0.97 (0.46, 2.06)
Calcium	490	0.64 (0.37, 1.12)	0.64 (0.37, 1.11)
Vitamin D	1303	0.92 (0.63, 1.36)	0.91 (0.62, 1.34)
Thiazide diuretics	262	0.95 (0.54, 1.67)	0.94 (0.53, 1.66)
Analgesics	1220	0.92 (0.61, 1.38)
Gabapentin	164		1.39 (0.75, 2.58)
Pregabalin	146		1.55 (0.86, 2.79)
Opioids	546		1.25 (0.85, 1.83)
Other Analgesics	959		0.94 (0.64, 1.37)
Dual-action antidepressants	277	1.22 (0.72, 2.08)
Duloxetine	207		0.68 (0.34, 1.34)
Tricyclic antidepressants	124	1.06 (0.54, 2.08)
Amitriptyline	102		1.38 (0.7, 2.71)
SSRIs antidepressants	333	1.54 (1, 2.36)	1.39 (0.9, 2.14)
Inhaled Glucocorticoids	189	1.42 (0.73, 2.77)	1.39 (0.7, 2.74)
Anti-hypertensive drugs	646	1.06 (0.7, 1.6)
ACE inhibitors	363		0.98 (0.58, 1.65)
ARBs	290		1.05 (0.62, 1.76)
Chronic NSAIDs	318	0.94 (0.57, 1.56)	0.95 (0.58, 1.55)

ACE = angiotensin-converting enzyme. ARBs = angiotensin II receptor blockers. CV = cardiovascular disease. hsCOVID-19 = highly suspected COVID-19 cases. NSAIDs = non-steroid anti-inflammatory drugs. SSRIs = selective serotonin reuptake inhibitors.